Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant
Por um escritor misterioso
Descrição
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial - ScienceDirect
Cancers, Free Full-Text
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial - Shenderov - 2021 - The Prostate - Wiley Online Library
Immunotherapy in Prostate Cancer: Recent Advances and Future Directions - European Medical Journal
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Frontiers Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies - McGregor - 2021 - Cancer - Wiley Online Library
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
